Richard D. Carvajal

TL;DR: It is demonstrated that intra-arterial melphalan can result in nonsustained tumor regression of recurrent orbital uveal melanoma, and it suggests that local delivery of high-dosemelphalan may be helpful as a neoadjuvant treatment for uveAL melanoma.

TL;DR: Findings from Delyon et al suggest that signal transducer and activator of transcription 3 activation may be an important mediator of response to nilotinib.

TL;DR: In this paper, a case of oral mucosal melanoma that recurred despite multiple resections and adjuvant temozolomide treatment with topical imiquimod combined with pembrolizumab achieved remission.

TL;DR: This work has potential to improve the quality of care for patients with complex medical conditions, particularly if the underlying condition is known to be musculoskeletal in nature.

TL;DR: The latest findings in melanoma research, including insights into the tumor microenvironment and new biomarkers, improved understanding of tumor immune response and resistance, novel approaches for combination strategies and the role of neoadjuvant and adjuvant therapy were the focus of discussions at the Melanoma Bridge meeting, which are summarized in this report.